Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

The shed phase from using finasteride and minoxidil can vary, with some experiencing noticeable hair loss and others having minimal shedding. Despite initial shedding, many users report eventual hair regrowth and improvement, making the treatment worthwhile.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

KX-826 shows promising results for hair growth with fewer side effects, offering an alternative to finasteride and minoxidil. Users discuss combining it with minoxidil, dermarolling, and Nizoral for improved results.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.

The user started using 2.5 mg Minoxidil and 1.5 mg Finasteride five months ago, experienced initial shedding, saw progress, but is now concerned about recent hair loss. Another user reassures them that shedding is normal and suggests continuing the treatment.

The conversation is about finding online pharmacies to obtain tretinoin for hairline improvement, with suggestions including Amazon and nurx.com. Alternatives like adapalene are also mentioned.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

The user is experiencing a difficult shedding phase after starting a hair loss treatment with oral finasteride, topical minoxidil, and microneedling. Despite the shedding, they remain hopeful for regrowth and plan to continue the treatment, encouraged by others' positive results.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

The conversation discusses the challenges and experiences of using minoxidil, finasteride, and dutasteride for hair loss, focusing on the shedding phase and its impact on hair appearance. Users share their personal experiences, side effects, and hopes for improvement, with some considering or having undergone hair transplants.

A user received a topical finasteride solution from a pharmacy, which likely dissolved finasteride tablets instead of using pure finasteride powder, resulting in sediment. The user expressed dissatisfaction, expecting pure powder, and discussed the pros and cons of DIY solutions and the use of minoxidil with finasteride.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

The user is currently using 0.025% Pantostin but plans to switch to 0.1% Alfatradiol. They will also use high-dose Kx826, high-dose Minoxidil, and aggressive microneedling for hair regrowth.

The user experienced hair shedding with finasteride and found minoxidil helpful for regrowth but insufficient alone. They are considering dutasteride but are concerned about potential shedding similar to their experience with finasteride.

Increased scalp itching during shedding phases while on finasteride treatment may coincide with hair regrowth and recovery. This suggests that itching might not always indicate continued hair loss and could encourage persistence with the treatment.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.